Ocrelizumab (US)

Phase 3

Amgen Inc. (AMGN)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

AMGNPhase 3$219.9B

Ocrelizumab (US) Phase 3 Est. Readout

Ocrelizumab (US)• Relapsing-remitting Multiple Sclerosis (RRMS)152

Q2 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in Relapsing-remitting Multiple Sclerosis (RRMS)

View Full Landscape

Drug Information

Target Indication

Relapsing-remitting Multiple Sclerosis (RRMS)

Clinical Trial

NCT06700343

Last updated: 1/6/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AMGN

Amgen Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

Denosumab (AMG 162)Phase 3

Postmenopausal Osteoporosis

TarlatamabPhase 3

Small Cell Lung Cancer

romosozumab HCP administration with PFSPhase 3

Post-Menopausal Osteoporosis

Etanercept LiquidPhase 3

Rheumatoid Arthritis

PegaspargasePhase 3

Acute Lymphoblastic Leukemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts